What the research found

GLP-1 receptor agonists—semaglutide, tirzepatide, and liraglutide—now carry FDA approvals for treating chronic kidney disease, cardiovascular events, obstructive sleep apnea, and fatty liver disease (MASH). This represents a fundamental shift: these drugs were originally developed for blood sugar control, then repurposed for weight loss, but regulatory approvals now centre on organ protection. The evidence behind these approvals shows measurable benefits—a 20% reduction in cardiovascular events in people without diabetes, a 24% reduction in major kidney-disease events, and resolution of liver inflammation in roughly 63% of patients treated for fatty liver disease. Notably, tirzepatide became the first drug approved specifically for sleep apnea.

The real-world picture supports this reframing. A nationally representative survey found that only 30% of GLP-1 users cite weight loss as their primary reason for taking the drug, while 70% report treating chronic conditions or combining treatment with weight management. Claims data from 2018–2024 shows that over half of established GLP-1 users already had diagnoses associated with organ disease—obstructive sleep apnea in 25.5%, depression in 18.2%, chronic kidney disease in 10.6%, and fatty liver disease in 10.3%—before expanding their use. The patient population taking these drugs grew 635% during this period.

Why it matters for you

If you're tracking GLP-1 use, the therapeutic logic now extends far beyond a scale reading. These drugs simultaneously lower blood pressure, reduce inflammation, and improve metabolic markers—all levers on organ function. Your MyKine biomarkers (kidney function markers like creatinine and eGFR, liver enzymes, lipids, blood pressure) directly reflect what regulators are now measuring in trials. A GLP-1 may improve these markers independently of weight loss, and the dose or choice of agent might be optimised around organ protection rather than body composition.

For users with sleep tracking, the obstructive sleep apnea approval changes the conversation: GLP-1s aren't just a side effect buffer for metabolic health, they're a primary intervention for breathing mechanics. If you're monitoring your own sleep quality or apnoea-hypopnoea index alongside peptide use, that's now a primary therapeutic endpoint, not a secondary benefit. Similarly, if you track liver ultrasounds, transient elastography, or biomarkers like FibroTest alongside metabolic work, GLP-1s are increasingly being selected for that indication specifically.

Caveats

  • Clinical trials ≠ real-world effectiveness: The presence of a diagnosis in claims data is correlation, not proof that GLP-1s are treating or benefiting that condition in each patient.
  • Self-reported survey data: The KFF poll relies on patient recall about why they take the drug and which diagnoses they carry; medical charts may differ.
  • One high-profile failure: Semaglutide missed its primary endpoint in early Alzheimer's disease trials, showing that organ indications are not automatic.
  • Short follow-up in some indications: Approval for sleep apnea and MASH is very recent; long-term safety and durability data remain limited.
  • Observational claims analysis: The Trilliant Health data captures filled prescriptions and diagnoses but cannot determine dosing, adherence, or which conditions were actually being treated.